Multiple-delayed release formulation approach for the treatment of methicillin-resistant Staphylococcus aureus

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 11, 2008, Pages 1313-1319

  Kurosu, Michio ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

Author keywords

Combination therapy; Dihydrofolate reductase inhibitor; Dihydropteroate synthase inhibitor; LexA protease cleavage inhibitor; Methicillin resistant Staphylococcus aureus (MRSA); Phenazine antibiotic; RNA polymerase inhibitor; Time controlled pulsatile delivery system

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GLYCOPEPTIDE; LINEZOLID; MACROLIDE; PENEM DERIVATIVE; PENICILLIN DERIVATIVE; PHENAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFAMETHOXAZOLE; TIGECYCLINE; TRIMETHOPRIM; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; COMBINATION CHEMOTHERAPY; DELAYED DRUG RELEASE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; HOSPITAL INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; NONHUMAN; PULSATILE DRUG RELEASE; STRUCTURE ANALYSIS; UNSPECIFIED SIDE EFFECT;

EID: 56849121288     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.11.1313     Document Type: Article

References (50)

1. Renet K, Guillemot D, Jarlier V, et al. Antibacterial resistance, Wayampis Amerindians, French Guyana. Emerg Infect Dis 2004;10:1150-4
2. Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:S386-93
3. Cunha BA. Vancomycin revisited: a reappraisal of clinical use. Crit Care Clin 2008;24:393-420
4. Loffler CA, MacDougall C. Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. Expert Rev Anti Infect Ther 2007;5:961-81
5. Tacconelli E, Cataldo MA. Antimicrobial therapy of Staphylococcus aureus bloodstream infection. Expert Opin Pharmacother 2007;8:2505-18
6. Klevens RM, Edwards JR, Tenover FC, et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006;42:389-91
7. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Healthcare Epidemiol 2005;41:848-54
8. Kluytmans-Vandenbergh MFQ, Kluytmans JAJW. Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infec 2006;12:9-15
9. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007;13:1840-6
10. Eady EA, Cove JH. Staphylococcal resistance revisited: community-acquired methicillin-resistant Staphylococcus aureus - an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis 2003;16:103-24
11. Diederen BMW, Kluytmans JAJW. The emergence of infections with community-associated methicillin resistant Staphylococcus aureus. J Infect 2006;52:157-68
12. Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Engl 2003;42:2010-23
13. Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6:2315-26
14. Schentag JJ, Hyatt JM, Carr JR, et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA), how treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium, and the importance of antibiotic management and infection control. Clin Infect Dis 1998; 26:1204-14
15. Donadio S, Soiso M. Biosynthesis of glycopeptides: prospects for improved antibacterials. Curr Top Med Chem 2008;8:654-66
16. Pace JL, Yang G. Glycopeptides: update on an old successful antibiotic class. Biochem Pharmacol 2006;71:968-80
17. Gales AC, Sader HS, Andrade SS, et al. Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in patient with cysteic fibrosis. Int J Antimicrob Agents 2007;27:300-2
18. Schmidt-Ioanas M, De Roux A, Lode H. New antibiotics for the treatment of severe staphylococcal infection in the critically ill patient. Curr Opin Crit Care 2005;11:481-6
19. Henck J-O, Byrrn SR. Designing a molecular delivery system within a preclinical timeframe. Drug Discov Today 2007;12:189-99
20. Anonymous: amoxicillin pulsatile MiddleBrook: APC 111, APC-111, PULSYS-enhanced amoxicillin. Drugs in R D 2007;8:395-9
21. Rayner C, Munchhof WJ. Antibiotics currently used in the treatment of infections caused Staphylococcus aureus. Int Med J 2005;35:S3-16
22. Gosbell IB. Methicillin-resistant Staphylococcus aureus: impact on dermatology practice. Am J Clin Dermatol 2004;5:239-59
23. Batts DH, Dekoning TF. Combination of Gyrase B inhibitors and protein synthesis inhibitors and uses thereof. WO2007142725; 2007
24. Srinivas J. Formulation comprising of ceftazidime, tazobactam and linezolid. PCT Int. Appl; 2007. p. 21
25. Graham S, Coote PJ. Potent, synergistic inhibition of Staphylococcus aureus upon exposure to a combination of the endopeptidase lysostaphin and the cationic peptide ranalexin. J Antimicrob Chemother 2007;59:759-62
26. Jacqueline C, Navas D, Batard E, et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicro Agents Chemother 2005;49:45-51
27. Nagasawa Z, Kusaba K, Takayanagi M, et al. Detection method of β-lactam antibiotic induced vancomycin-resistant MRSA and combined effects of antibiotics against MRSA. Nippon Kagaku Ryoho Gakkai Zasshi 2003;51:631-7
28. Pexher JC, Tancrede C, Tancrede D. In vitro study of the bactericidal activity of a sulfamethoxazole-trimethoprim combination of 59 hospital strains. Therapie 1970;25:13-28
29. Schiraldi O, Sforza E, Piaia F. Effect of a new sulfa- trimethoprim combination (trimethoprim -sulfamethopyrazine) in typhoid fever. A double-blind study on 72 adult patients. Chemotherapy 1985;31:68-75
30. Bohni E. Comparative bacteriological investigations with the combination trimethoprim/sulfamethoxazole in vitro and in vivo. Chemotherapy 1969;14:1-21
31. Miyamoto E. Oral trimethoprim-sufamethoxazole for methicillin-resistant Staphylococcus aureus infections: the evidence behind the use. Drug Ther Topics 2004;33:69-74
32. Roccaforte JS, Bittner MJ, Stumpf CA, Preheim LC. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin. Am J Infect Control 1988;16:141-6
33. Hoffman A, Horwitz E, Hess S, et al. Implications on emergence of antimicrobial resistance as a critical aspect in the design of oral sustained release delivery systems of antimicrobials. Pharm Res 2008;25:667-71
34. Anal AK. Time-controlled pulsatile delivery system for bioactive compounds. Recent Patents Drug Deliv Formulation 2007;1:73-9
35. Maroni A, Zema L, Cerea M, Sangalli ME. Oral pulsatile drug delivery systems. Expert Opin Drug Deliv 2005;2:855-71
36. Bussemer T, Bodmeier R. A review of pulsatile drug delivery. Am Pharm Rev 2001;4:18-22
37. Bussemer T, Otto I, Bodmeier R. Pulsatile drug-delivery systems. Crit Rev Ther Drug 2001;18:433-58
38. Makino K. Time-controlled drug release devices. Farumashia 2001;37:382-4
39. Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliver Rev 2002;54:53-77
40. Available from: www.eurand.com
41. Liu J, Ren HP. Tuberculosis: current treatment and new drug development. Anti-Infect. Agents Med Chem 2006;5:331-44
42. Conley C, Roush J, Storm K. Once daily dosing formulations for amoxicillin and clavulanic acid. PCT Int. Appl; 2002. p. 28
43. New HC. Synergy and antagonism of combinations with quinolones. Eur J Clin Microbiol Infect Dis 1991;10:255-61
44. Holm SE. Interaction between β-lactam and other antibiotics. Reviews Infect Dis 1986;8:S305-14
45. Giddens SR, Bean DC. Investigations into the in vitro antimicrobial activity and mode of action of the phenazine antibiotic D-alanylgriseluteic acid. Int J Antimicro Agents 2007;29:93-7
46. Price-Whelan A, Dietrich LEP, Newman DK. Rethinking secondary metabolism: physiological roles for phenazine antibiotics. Nature Chem Biol 2006;2:71-8
47. Feldman AR, Lee J, Delelmas B, Paetzel M. Crystal structure of a novel viral protease with a serine/lysine catalytic dyad mechanism. J Mol Biol 2006;358:1378-89
48. Cirz RT, Romesberg FE. Induction and inhibition of ciprofloxacin resistance-conferring mutations in hypermutator bacteria. Antimicrob Agents Chemother 2006;50:220-5
49. Da Cunha EFF, Ramalho TC, Maia ER, De Alencastro RB. The search for new DHFR inhibitors: a review of patents January 2001-February 2005. Expert Opin Ther Patents 2005;15:967-86
50. Hawser S, Lociuro S, Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 2006;71:941-8